Research programme: kallikrein inhibitors - BioCryst
Latest Information Update: 28 Jan 2018
At a glance
- Originator BioCryst Pharmaceuticals
- Class Small molecules
- Mechanism of Action Bradykinin inhibitors; Kallikrein inhibitors; Tissue factor-factor VIIa complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hereditary angioedema
- Discontinued Acute coronary syndromes; Cancer; Coronary artery restenosis
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Hereditary-angioedema in USA (PO)
- 20 Dec 2013 Preclinical trials in Hereditary angioedema in USA (PO)
- 28 Mar 2013 Early research in Hereditary angioedema in USA (PO)